Explore a selection of our essential drug information below, or:
Overview
- Description
- A component of an inactivated influenza vaccine that uses killed (i.e. inactivated) influenza virus to generate an immune response.
- Description
- A component of an inactivated influenza vaccine that uses killed (i.e. inactivated) influenza virus to generate an immune response.
- DrugBank ID
- DB18750
- Type
- Biotech
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 0
- Phase 2
- 0
- Phase 3
- 0
- Phase 4
- 0
Identification
- Summary
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated) is a component of an inactivated influenza vaccine.
- Brand Names
- Fluzone 2023-2024, Fluzone 2024-2025, Fluzone High-Dose Quadrivalent, Fluzone Quadrivalent, Fluzone Quadrivalent Southern Hemisphere
- Generic Name
- Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
- DrugBank Accession Number
- DB18750
- Background
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen". This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
There are three basic types of vaccines available: inactivated influenza vaccine (IIV), live attenuated influenza vaccine (LAIV), and recombinant influenza vaccines (RIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability. Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Fluzone High Dose Northern Hemisphere Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (60 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Inc. 2024-07-01 2025-06-30 US 
Fluzone High-Dose Quadrivalent Northern Hemisphere Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (60 ug/0.7mL) Injection, suspension Intramuscular Sanofi Pasteur Inc. 2024-07-01 2025-06-30 US FLUZONE High-Dose Quadrivalent Southern Hemisphere Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (60 ug/0.7mL) Injection, suspension Intramuscular Sanofi Pasteur Inc. 2024-03-26 2024-12-31 US Fluzone Quadrivalent Northern Hemisphere Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Inc. 2024-07-01 2025-06-30 US Fluzone Quadrivalent Northern Hemisphere Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Inc. 2024-07-01 2025-06-30 US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 17, 2024 17:11 / Updated at May 17, 2024 18:02